Helsinn Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Helsinn Therapeutics's estimated annual revenue is currently $102.3M per year.
- Helsinn Therapeutics's estimated revenue per employee is $201,000
Employee Data
- Helsinn Therapeutics has 509 Employees.
- Helsinn Therapeutics grew their employee count by -11% last year.
Helsinn Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | VP | Reveal Email/Phone |
2 | CMO Planner | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | VP, US Sales and Marketing | Reveal Email/Phone |
5 | VP and Head, Medical & Scientific Affairs | Reveal Email/Phone |
6 | Head Portfolio Management | Reveal Email/Phone |
7 | Regulatory Affairs Officer | Reveal Email/Phone |
8 | Head Medical Science | Reveal Email/Phone |
9 | Controller | Reveal Email/Phone |
10 | Group Compliance Officer and Group Head Compliance & Quality | Reveal Email/Phone |
Helsinn Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Helsinn Therapeutics?
Welcome! Thank you for connecting to Helsinn’s LinkedIn profile.\nHelsinn would like to emphasize and make you aware that due to the highly regulated nature of the pharma industry, we cannot engage with you online in sensitive discussions or topics concerning our or other companies’ products and/or services, and/or treatment options. It is best to hold such discussions and to seek guidance privately from your healthcare professional. \n\n\nHelsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care and rare disease products and a broad development pipeline. Since 1976, Helsinn, focused on the development of new treatments to fulfill more medical needs and on improving the everyday lives of patients, all guided and underpinned by core family values of respect, integrity and quality. \n\nThe Group works across pharmaceuticals, biotechnology and medical devices and has expertise in research and development, manufacturing and commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology.\n\nIn 2016, Helsinn launched the Helsinn Investment Fund to support the future of innovation in healthcare and advance early-stage opportunities by providing funding and strategic support to innovative healthcare companies in areas of unmet patient need.\n\nThe company is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland, the US, Monaco and in China as well as a product presence in about 190 countries globally.\n\nA modern Group focused on growth and development but also tied to tradition and on the values of a family business: in Helsinn more than 700 employees work not only for the health of the patient, but overall for the quality of life of the person.
keywords:N/AN/A
Total Funding
509
Number of Employees
$102.3M
Revenue (est)
-11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Helsinn Therapeutics News
Arginase Deficiency Therapeutics Market Size, Scope And Forecast | Leading Players Helsinn Healthcare, Novartis Pharmaceuticals, Medicis...
Just over a year later, in May 2021, the FDA approved infigratinib (Truseltiq®; Helsinn Therapeutics (U.S.) and QED Therapeutics),...
(hereinafter Taiho) and Helsinn Group (hereinafter Helsinn), announced today that Taiho has been granted approval from the Japanese Ministry...
3B FUTURE HEALTH GP S.a.r.l. launches the 3B Future Health Fund II. The Fund is focused on early-stage investment opportunities in areas of high unmet patient need and follows the success of 3B Future Health Fund I, formerly known as Helsinn Investment Fund. The investment focus for the Fund is ...
→ Swiss pharma group Helsinn is acquiring rights to skin cancer drug Valchlor (marketed as Ledaga in Europe) from Actelion Pharmaceuticals. The deal gets Helsinn worldwide rights to the rare disease drug, which is a topical drug for mycosis fungoides-type cutaneous T-cell l ...